0001193125-24-035631.txt : 20240314 0001193125-24-035631.hdr.sgml : 20240314 20240214115957 ACCESSION NUMBER: 0001193125-24-035631 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kura Oncology, Inc. CENTRAL INDEX KEY: 0001422143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 611547851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 500-8800 MAIL ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP III DATE OF NAME CHANGE: 20071227 CORRESP 1 filename1.htm CORRESP

Kura Oncology, Inc.

12730 High Bluff Drive

Suite 400

San Diego, CA 92130

(858) 500-8800

February 14, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Daniel Crawford

 

Re:

Kura Oncology, Inc.

Registration Statement on Form S-3

File No. 333-276995

Ladies and Gentlemen:

Kura Oncology, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:00 p.m. Eastern Time on Wednesday, February 14, 2024, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Charles J. Bair of Cooley LLP and Wade W. Andrews of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Charles J. Bair at (858) 550-6142, or in his absence, Wade W. Andrews at (858) 550-6042.

Sincerely,

KURA ONCOLOGY, INC.

 

By:

  

/s/ Troy E. Wilson, Ph.D., J.D.

 

Troy E. Wilson, Ph.D., J.D.

 

President and Chief Executive Officer

 

cc:

Charles J. Bair, Cooley LLP

Wade W. Andrews, Cooley LLP